Interventional Spine
10+ Year Member
May 13, 2007
New Orleans, LA
  1. Attending Physician
    Recalled Narcotic Analgesic Returning to Market
    Pfizer announced that the FDA has approved a Prior Approval Supplement for Embeda (morphine sulfate and naltrexone HCl) Extended-Release Capsules.

    Embeda is a Schedule II narcotic indicated for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

    RELATED: Pain Management Resource Center

    Embeda was voluntarily recalled in March 2011 because it did not meet a prespecified stability requirement during routine testing. The Prior Approval Supplement included an update to the Embeda manufacturing process that addressed the pre-specified stability requirement.

    Embeda extended-release capsules will be available in 20mg/0.8mg and 30mg/1.2mg as 75-count bottles; 50mg/2mg as 150-count bottles; 60mg/2.4mg and 80mg/3.2mg as 200-count bottles; and 100mg/4mg as 300-count bottles. Pfizer anticipates it will be available in the second quarter of 2014.

    For more information call (800) 438-1985 or visit Embeda.com.
    About the Ads
    This thread is more than 7 years old.

    Your message may be considered spam for the following reasons:

    1. Your new thread title is very short, and likely is unhelpful.
    2. Your reply is very short and likely does not add anything to the thread.
    3. Your reply is very long and likely does not add anything to the thread.
    4. It is very likely that it does not need any further discussion and thus bumping it serves no purpose.
    5. Your message is mostly quotes or spoilers.
    6. Your reply has occurred very quickly after a previous reply and likely does not add anything to the thread.
    7. This thread is locked.